Please assess the completion status of the following clinical trial:

Trial Title: Dehydroepiandrosterone (DHEA) and Letrozole in Treating Patients With Metastatic Breast Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Diagnosis of breast cancer~  * Metastatic disease~* Hormone receptor status~  * Estrogen receptor- and progesterone receptor-negative~ * Androgen receptor-positive~PATIENT CHARACTERISTICS:~* ECOG performance status 0-3~* Postmenopausal (\> 60 years of age)~* Leukocyte count \> 3,000/uL~* Absolute neutrophil count \> 1,500/uL~* Platelet count \> 100,000/uL~* Total bilirubin normal~* AST and ALT \< 2.5 times upper limit of normal~* Creatinine normal OR creatinine clearance \> 60 mL/min~PRIOR CONCURRENT THERAPY:~* At least 4 weeks since prior chemotherapy~* At least 4 weeks since prior biologic therapy~* At least 4 weeks since prior radiotherapy~* At least 30 days since prior investigational agents~* No concurrent dehydroepiandrosterone or androstenedione supplements~* No concurrent chemotherapy or radiotherapy~* No concurrent hormone therapy or immunotherapy (including trastuzumab \[Herceptin®\])

- Gender: ALL
- Minimum Age: 60 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).